详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Expression of immune checkpoints in T cells of esophageal cancer patients

文献详情

资源类型：

收录情况： ◇ SCIE

作者：

机构： [1]Cancer Center, Hai’an Hospital Affiliated to Nantong University, Hai’an, China [2]Department of Oncology, the Second Affiliated Hospital of Soochow University, Suzhou, China [3]The Central Laboratory, Hai’an Hospital Affiliated to Nantong University, Hai’an, China [4]Cyrus Tang Hematology Center, Soochow University, Suzhou, China

出处：

DOI：

ISSN：

关键词： esophageal cancer immune checkpoints PD-1 TIM-3 cancer immunotherapy

摘要：

Inhibition of immune checkpoint proteins (checkpoints) has become a promising anti-esophageal cancer strategy. We here tested expressions of immune checkpoints in human esophageal cancers. Our results showed the expressions of many immune checkpoints, including CD28, CD27, CD137L, programmed death 1 (PD-1), T cell immunoglobulin mucin-3 (TIM-3), T cell Ig and ITIM domain (TIGIT), CD160, cytotoxic T lymphocyte antigen 4 (CTLA-4), CD200, CD137 and CD158, were dysregulated in peripheral T cells of esophageal cancer patients. Further, the expressions of PD-1, TIM-3 and TIGIT were upregulated in tumor infiltrating lymphocytes (TILs), which might be associated with TILs exhaustion. Meanwhile, the expressions of PD-1 and TIM-3 on CD4+ T cells were closely associated with clinic pathological features of esophageal cancer patients. These results indicate that co-inhibitory receptors PD-1, TIM-3 and TIGIT may be potential therapeutic oncotargets for esophageal cancer.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2015]版：

大类 | 1 区

医学

小类 | 2 区肿瘤学 3 区细胞生物学

最新[2025]版：

无

JCR分区：

出版当年[2014]版：

Q1 ONCOLOGY Q1 CELL BIOLOGY

最新[2023]版：

无

影响因子： 0 最新[2023版] 0 最新五年平均 6.359 出版当年[2014版] 6.368 出版当年五年平均 6.627 出版前一年[2013版] 5.008 出版后一年[2015版]

第一作者：

第一作者机构： [1]Cancer Center, Hai’an Hospital Affiliated to Nantong University, Hai’an, China

共同第一作者：

通讯作者：

通讯机构： [1]Cancer Center, Hai’an Hospital Affiliated to Nantong University, Hai’an, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Immune escape mechanisms and immunotherapy of urothelial bladder cancer. [2]Biological Response Modifier in Cancer Immunotherapy [3]Tim-3 ligand galectin-9 reduces IL-17 level and accelerates Klebsiella pneumoniae infection [4]Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples [5]Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas [6]Esophageal cancer in elderly patients: a population-based study [7]N6-methyladenosine participates in mouse hippocampus neurodegeneration via PD-1/PD-L1 pathway [8]Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors [9]Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas [10]Manipulating Liver Bile Acid Signaling by Nanodelivery of Bile Acid Receptor Modulators for Liver Cancer Immunotherapy.